272 results about "Oncolytic virus" patented technology

The invention provides isolated monoclonal antibodies that specifically bind to human Claudin 18.2. Nucleic acid molecules for encoding the antibodies, as well as expression vectors, host cells and methods for expressing the antibodies are also provided. The invention also provides immunoconjugates, bispecific molecules, chimeric antigen receptors, oncolytic viruses and pharmaceutical compositionscomprising the antibodies, and methods for diagnosis or treatment using the antibodies.

Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.

The present invention provides methods for treating an individual having solid or lymphatic tumor comprising locally administering to the site of the tumor an oncolytic virus, and systemically administering an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor a second immunomodulator (including a combination of immunomodulators). Also provided are compositions and kits for the cancer therapy methods.

The invention provides a recombinant II type herpes simplex virus vector. An ICP34.5 gene and an ICP47 gene of a wild II type herpes simplex virus HG52 strain are removed in the virus vector, and preferably a human granulocyte macrophage-colony stimulating factor (hGM-CSF) expression box is inserted into the position where the ICP34.5 gene is removed. The invention also provides a preparation method of the recombinant II type herpes simplex virus vector, a recombinant virus using the recombinant II type herpes simplex virus as a vector, a medicinal composition consisting of the recombinant II type herpes simplex virus vector and a pharmaceutically acceptable vector or excipient, and application of the recombinant II type herpes simplex virus vector in preparation of a gene medicament for treating tumors. As the ICP34.5 gene is removed in the recombinant II type herpes simplex virus vector provided by the invention, the oncolysis virus is safe and can selectively grow and propagate in tumor cells; the ICP47 gene is removed to promote immune response and enhance oncolysis activity; and the curative effect of the recombinant II type herpes simplex virus vector is superior to that of the conventional recombinant I type herpes simplex virus vector, and the recombinant II type herpes simplex virus vector has high safety.

The invention provides a site-directed modification method for DNA viral genome, and the problems in the prior art are solved that induction of site-directed mutagenesis of DNA viral genome is difficult, the operation of inserting an exogenous fragment is complex, and recombination rate is lower. The site-directed modification method comprises: transfecting cells by a plasmid carrying a nuclease system, infecting by a virus, after the cells show pathological changes, collecting the cells with pathological changes, performing freeze-thaw or ultrasonic processing, and centrifuging, separating the liquid supernatant to obtain a progeny virus. The site-directed modification method is capable of realizing applications to screening of virus attenuated vaccine strains, construction of viral genetic carriers and an oncolytic virus, research on virus function sequences, and the like; during modification of the viral genome, the method helps to improve mutagenesis efficiency, accurately control DNA virus for genome site-directed mutagenesis and specific gene knockout, simplify operation steps of inserting the DNA virus carrier by an exogenous gene, and improve efficiency that the exogenous gene is integrated to the viral genome, so that the work of screening high-flux recombination viruses is convenient to conduct.

The invention belongs to the field of biological medicine and relates to an application of a VCP (valosin containing protein) inhibitor and an oncolytic virus in preparation of antitumor drugs. The invention discovers that the VCP inhibitor can be used for preparing an oncolytic virus antitumor synergist. Meanwhile, the invention relates to pharmaceutical composition containing the VCP inhibitor and the oncolytic virus, a drug suit containing the VCP inhibitor and the oncolytic virus as well as an application of the VCP inhibitor and the oncolytic virus in treatment of tumors, especially tumors insensitive to the oncolytic virus. Besides, the invention relates to an antitumor medication system, and the system is characterized by comprising a VCP expression level detection reagent and the oncolytic virus.

The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus ('SVV'). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.

The present invention provides an isolated monoclonal antibody that specifically binds to human OX40. Also provided are nucleic acid molecules encoding the antibody, an expression vector, a host celland a method for expressing the antibody. The invention also provides immunoconjugates, bispecific molecules, chimeric antigen receptors, oncolytic viruses, and pharmaceutical compositions comprisingthe antibody, as well as methods of treatment using the antibody of the invention.

Methods for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer and persistent viral infections, are described. A method may comprise priming a mammal by administering to the mammal an effective amount of a nucleic acid composition encoding an antigen or a biologically active homolog thereof and boosting the mammal by administering to the mammal an effective amount of an oncolytic virus comprising a nucleic acid encoding the antigen or the biologically active homolog thereof.

The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and / or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.

The invention discloses a novel oncolytic virus based on vaccinia virus Tiantan strain. The thymidine kinase (TK) region of the virus contains a coding sequence of AIF-GM-CSF as shown in SEQ ID NO.1.The oncolytic vaccinia virus which can efficiently expressing a human AIF-GM-CSF gene is prepared by effectively combining the tumor suppression effect of gene therapy and the oncolytic effect of viral therapy. While the oncolytic virus of the vaccinia virus Tiantan strain achieves the oncolytic effect to pyrolyze tumor cells, human AIF is massively expressed to cause apoptosis of a great number of infected tumor cells; and a great number of human GM-CSF can be expressed, and NK cells or DC cells can be recruited into the inside of a tumor to kill the tumor or effectively represent a tumor antigen, so that proliferation and differentiation of cytotoxicity t cells can be improved, and multiple anti-tumor effects can be achieved. Compared with simple gene therapy or virus therapy, the malignant tumor killing performance of the novel oncolytic virus is reinforced.

The present invention provides an expression system, the system comprising: a first nucleic acid molecule having a cell specific promoter; a second nucleic acid molecule encoding a transcriptional activator; a third nucleic acid molecule having a first recognition sequence of the transcriptional activator; a fourth nucleic acid molecule having a first promoter and a first regulatory element; a fifth nucleic acid molecule encoding a first regulatory protein; a sixth nucleic acid molecule having a second recognition sequence of the transcriptional activator; a seventh nucleic acid molecule having a second promoter and a second regulatory element; an eighth nucleic acid molecule encoding a second regulatory protein; and: a ninth nucleic acid molecule configured to conditionally inhibit expression of the first regulatory protein; and a tenth nucleic acid molecule configured to conditionally inhibit expression of the second regulatory protein, wherein the first regulatory element is adaptedto inhibit the function of the first promoter by binding to the second regulatory protein, and the second regulatory element is adapted to inhibit the function of the second promoter by binding to the first regulatory protein.

The invention belongs to the technical field of biology, and particularly relates to an oncolytic virus vaccine and a medicine for treating tumors by combining the oncolytic virus vaccine with immunecells. The invention provides a brand-new oncolytic virus attenuated strain by carrying out site-specific mutagenesis on the VSV wild type virus matrix protein M. The gene sequence of the matrix protein M is shown as SEQ ID NO 3. The attenuated strain can be independently used as a drug for treating tumors, and is superior to wild type viruses and other known attenuated strains in safety and curerate. On the basis of the oncolytic virus attenuated strain, NY-ESO-1 is inserted into the attenuated strain, and the invention further provides a vaccine capable of being applied to tumor treatment.The vaccine is high in cure rate and high in biological safety. On the basis of the vaccine, the vaccine and TCR-T cells are combined for application, and a medicine capable of efficiently treating various tumors is provided. On a mouse lung cancer model, the cure rate can reach the surprising rate of 95 percent.

The present invention is directed oncolytic Herpes simplex-1 viruses whose replication is controlled using a tetracycline operator / repressor system. The invention also includes DNA sequences used in making the viruses and methods in which these viruses are used in the treatment of cancer patients with solid tumors.